Posted by Michael Wonder on 19 Nov 2022
FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)
18 November 2022 - Today, the FDA approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals).
Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. It also is approved to be administered every 48 hours at a dose of 25 mg/m2 intramuscularly.
